https://www.selleckchem.com/products/sr10221.html
7 vs 14.2months and 8 vs 16months, respectively;p = 0.04). No association between the selected SNP and the overall survival was found. These findings suggest an association between CYP17A1 c.-362TCpolymorphism and poorer clinical outcome with abiraterone for mCRPC patients. However, further validations on larger cohort of patients are needed to confirm its role as a predictive biomarker for abiraterone resistance. C polymorphism and poorer clinical outcome with abiraterone for mCRPC patients. However, further validations on larger c
Like
Comment
Share
